KU-0063794

Catalog No.S1226

For research use only.

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

KU-0063794 Chemical Structure

CAS No. 938440-64-3

Selleck's KU-0063794 has been cited by 65 publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Other mTOR Products

Biological Activity

Description KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.
Targets
mTORC1 [1]
(Cell-free assay)
mTORC2 [1]
(Cell-free assay)
~10 nM ~10 nM
In vitro

Compared with the mTOR inhibitor PP242, KU-0063794 exhibits higher specificity for mTOR, as being inactive against PI3Ks or 76 other kinases. In HEK-293 cells, KU-0063794 at 30 nM is sufficient to rapidly ablate S6K1 activity by blocking the phosphorylation of the hydrophobic motif (Thr389) and subsequently the phosphorylation of the T-loop residue (Thr229). In case of IGF1 stimulation of serum-starved HEK-293 cells, 300 nM of KU-0063794 is needed to inhibit the S6K1 activity by ~90%. KU-0063794 at 100-300 nM also completely inhibits the amino-acid-induced phosphorylation of S6K1 and S6 protein. Similar to S6K1, KU-0063794 inhibits the phosphorylation of mTORC1 at Ser2448 and mTORC2 at Ser2481 in a dose-dependent and time-dependent manner. In the presence of serum or following IGF1 stimulation, KU-0063794 induces a dose-dependent inhibition of the activity and phosphorylation of Akt at Ser473 and unexpected Thr308 as well as the phosphorylation of the Akt substrates PRAS40 at Thr246, GSK3α/GSK3β at Ser21/Ser9 and Foxo-1/3a at Thr24/Thr32. KU-0063794 but not rapamycin inhibits SGK1 activity and Ser422 phosphorylation as well as its physiological substrate NDGR1 in a dose-dependent manner, to the same extent as S6K1 and Akt phosphorylation, whereas KU-0063794 dose not inhibit phorbol ester induced ERK or RSK phosphorylation and RSK activation. Compared with rapamycin, KU-0063794 exhibits more significant potency to induce the complete dephosphorylation of 4E-BP1 at Thr37, Thr46 and Ser65. KU-0063794 inhibits cell growth of both wild-type and mLST8-deficient MEFs and induces a G1 cell cycle arrest, more significantly than rapamycin. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2  M17ybWNmdGxiVnnhZoltcXS7IFHzd4F6 MXuwMlHjiJN3MNMg{txO MUi3NkBp NFvrelZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ5OEixPUc,OjZ{N{i4NVk9N2F-
HepG2  NWnLN3pNS2:ub375JGZwem2jdHnvckBCe3OjeR?= M1\5[FHjiJN3MNMg{txO MUKxNEBl M1\LbIRm[3KnYYPld{B1cGViboXtZoVzKG:oII\pZYJt\SCKZYDHNkBkd2yxbnnld:Khe2mpbnnmbYNidnSueR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ5OEixPUc,OjZ{N{i4NVk9N2F-
HepG2  MnzGRZBweHSxc3nzJGF{e2G7 MnrENE4y6oDVNUFCpO69VQ>? MV:0PEBp NUjPOVEzcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{N{i4NVkoRjJ4Mke4PFE6RC:jPh?=
HepG2  MVTGeY5kfGmxbjDBd5NigQ>? NEXHSVI2NzFyIN88US=> MWGyOEBp MUjkdoFu[XSrY3HscJkhcW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJvNEez NVLXSYpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yO|g5OTlpPkK2Nlc5QDF7PD;hQi=>
HepG2  M2H3UmZ2dmO2aX;uJGF{e2G7 MlvwOU8yOCEQvF2= M3Xnd|I1KGh? MX\kc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNiSFnGNe6yKGGwZDDjfYNtcW5iREJCpC=> M2j4UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mke4PFE6Lz5{NkK3PFgyQTxxYU6=
HepG2  MXLGeY5kfGmxbjDBd5NigQ>? NYH6NlBROC5z4pETOVDDqM7:TR?= NVOwdFd[OjRiaB?= MUXpcoR2[2W|IIC2NkBld3ewcnXneYxifGmxbjygRoVkdGmwLUGg[ZhxemW|c3nvckBidmRiTFOzRk1KKHSxIFzDN2IuUUliY3;ueoVze2mxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFTxWpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK3PFgyQSd-Mk[yO|g5OTl:L3G+
HepG3  NFPaT2hHfW6ldHnvckBCe3OjeR?= NFXuWWQxNjIkgKO1NOKh|ryP M1vwdVQ5KGh? NW\rO3cxcW6mdXPld{Bk\WyuIHH1eI9xcGGpeTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ5OEixPUc,OjZ{N{i4NVk9N2F-
AGS MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL4TWM2OD1zNT6wJOKyKDJwOUGg{txO NI\Pcos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5O|Q4QCd-MkS1PVc1Pzh:L3G+
HGC27 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf3dplKSzVyPUG1MlAhyrFiND64NkDPxE1? NGLpeVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5O|Q4QCd-MkS1PVc1Pzh:L3G+
MKN45 NWHUNmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jVcGlEPTB;MD64NkDDuSByLkCxJO69VQ>? M3vnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm3OFc5Lz5{NEW5O|Q4QDxxYU6=
NUGC4 NVPZNFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qe2lEPTB;Mj65N{DDuSByLkOxJO69VQ>? MonsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OUe0O|goRjJ2NUm3OFc5RC:jPh?=
PC9 M2nrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofSO|IhcA>? MYPJR|UxRTFyLkG1xtExNjZ{IH7N MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9GR M1fZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi4O|IhcA>? NH\INXhKSzVyPU[uNlHDuTFwM{Cgcm0> M3XhWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
H1650 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NkBp NGDrdmhKSzVyPUeuOlHDuTBwNkKgcm0> M2Dxb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
H1975 M1;iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLJOo5YPzJiaB?= NU\Sc4s1UUN3ME2xNU4yPcLzMD65N{BvVQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9 MkD1SpVv[3Srb36gRZN{[Xl? NX7XXnVEOTBwMUWgcm0> Mn;WO|IhcA>? NIDIcW1qdmirYnn0d{BuXE:UIIDoc5NxcG:{eXzheIlwdiC|dHH0eZPDqA>? NGH6XVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3OFg5OCd-MkO4O|Q5QDB:L3G+
PC9GR MUfGeY5kfGmxbjDBd5NigQ>? MlH0Ok4zOSCwTR?= MkP2O|IhcA>? MU\pcohq[mm2czDtWG9TKHCqb4PwbI9zgWyjdHnvckB{fGG2dYRCpC=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
H1650 NFvTOXJHfW6ldHnvckBCe3OjeR?= MYi3MlYyKG6P MlPxO|IhcA>? NU[xOppucW6qaXLpeJMhdVSRUjDwbI9{eGixconsZZRqd25ic4TheJV{yqB? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
H1975 NX3obFMyTnWwY4Tpc44hSXO|YYm= M1P2WFEyNjF3IH7N MmrsO|IhcA>? MnHqbY5pcWKrdIOgcXRQWiCyaH;zdIhwenmuYYTpc44he3SjdIXzxsA> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5NEi4NEc,OjN6N{S4PFA9N2F-
PC9 Mn\iSpVv[3Srb36gRZN{[Xl? NUXNb29pOTBwMUWgcm0> NX7NO3JqPzJiaB?= MmHHbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJA4OFN4Sx?= M2PlXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
PC9GR NEOwdXNHfW6ldHnvckBCe3OjeR?= MVu2MlIyKG6P NWDwR5RSPzJiaB?= MmfLbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJA4OFN4Sx?= M33x[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
H1650 NYfDWnZRTnWwY4Tpc44hSXO|YYm= NXSzb|NZPy54MTDuUS=> NV\tcpRmPzJiaB?= MlrKbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJA4OFN4Sx?= NXL2bnRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O|Q5QDBpPkKzPFc1QDhyPD;hQi=>
H1975 M1XFSmZ2dmO2aX;uJGF{e2G7 NHTHcncyOS5zNTDuUS=> MmL0O|IhcA>? MYHpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gdFcxWz[N M2LiO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEe0PFgxLz5{M{i3OFg5ODxxYU6=
LNCaP NFj6OolE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{jLOVAuOTBizszN Mlf1NlQhcMLi NXyxTWtP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC2NFUoRjJ|OESwOlA2RC:jPh?=
PC-3 NFPaeW5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVqwMVExKM7:TR?= MUCyOEBpyqB? NVzCbpNW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NUOwT3JHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFA3ODVpPkKzPFQxPjB3PD;hQi=>
MDA-MB-468  NYjIV3E1S2WubDDWbYFjcWyrdImgRZN{[Xl? NYDIUWFXOC1zMDFOwG0> M{HUZVI1KGkEoB?= MmjS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2ME[wOUc,OjN6NEC2NFU9N2F-
LNCaP NUT6[FBHTnWwY4Tpc44hSXO|YYm= MX:yNFDjiJN6MECgcm0> M2DUO|I1KGkEoB?= NVHzSJdG\GWlcnXhd4V{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Ywhd2ZicEewV|ZMKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC2NFUoRjJ|OESwOlA2RC:jPh?=
PC-3 NXTId2tETnWwY4Tpc44hSXO|YYm= MUGyNFDjiJN6MECgcm0> MkDLNlQhcMLi MX;k[YNz\WG|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBt\X[nbDDv[kBxPzCVNlugbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MkLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC2NFUoRjJ|OESwOlA2RC:jPh?=
MDA-MB-468  NYnJTXNCTnWwY4Tpc44hSXO|YYm= NFTxUYIzODEkgKO4NFAhdk1? MnzkNlQhcMLi NHPRbFVl\WO{ZXHz[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcEBw\iCyN{DTOmshcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Ml24QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEC2NFUoRjJ|OESwOlA2RC:jPh?=
Caki-1  M4XVS2Z2dmO2aX;uJGF{e2G7 M2jXSlExOC1{MECwJI5O NIDsRmkyOC1zOECgcYlv NYfiNZhNTE2VTx?= NW\GfYFPcW6qaXLpeJMh[m:2aDDtWG9TSzFiYX7kJI1VV1KFMjDhd{BqdmSrY3H0[YQh[nlidHjlJIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHnvckBw\iCmb4fud5Rz\WGvIHXm[oVkfG:{cx?= NEC1PZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0PVk5QSd-MkOzOFk6QDl:L3G+
786-O MknVSpVv[3Srb36gRZN{[Xl? M3LBPFExOC1{MECwJI5O MXuxNE0yQDBibXnu MV3EUXNQ Ml3LbY5pcWKrdIOgZo91cCCvVF;SR|Eh[W6mIH3UU3JEOiCjczDpcoRq[2G2ZXSgZpkhfGinIHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKGWoZnXjeI9zew>? NV7tdGVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFk6QDlpPkKzN|Q6QTh7PD;hQi=>
Caki-1  MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlnCN|AxNTRyMECgcm0> Ml\VNlQuQTZiaB?= MlvvSG1UVw>? MXPzeZBxemW|c3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NEXTeWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0PVk5QSd-MkOzOFk6QDl:L3G+
786-O Mlv4R4VtdCCYaXHibYxqfHliQYPzZZk> NHLsTIk{ODBvNECwNEBvVQ>? MX6yOE06PiCq M1nzOmROW09? NHzKbmV{fXCycnXzd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NIfmTIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0PVk5QSd-MkOzOFk6QDl:L3G+
Caki-1  MnXhSpVv[3Srb36gRZN{[Xl? MYKyJOK2VQ>? M4LtO|czKGh? MVvEUXNQ NY\SPHhLcW6mdXPld{BIOSClZXzsJIN6[2ynIHHydoV{fCCjbnSgZZV1d3CqYXf5 NVPRWIo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFk6QDlpPkKzN|Q6QTh7PD;hQi=>
786-O NXHoRY5nTnWwY4Tpc44hSXO|YYm= NWTTc2ljOiEEtV2= NGPWbGc4OiCq NGjSb2dFVVOR M1fIcYlv\HWlZYOgS|Eh[2WubDDjfYNt\SCjcoLld5Qh[W6mIHH1eI9xcGGpeR?= M2XKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{S5PVg6Lz5{M{O0PVk5QTxxYU6=
HEK293 M1[xWGZ2dmO2aX;uJIF{e2G7 NUXRVJhzOiCqcoO= M4LyRWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSmxCTy22YXfn[YQhdVSRUjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIXzbY5oKGKrb4Tpcplt[XSnZDDwO|BUPktic4Xid5Rz[XSnIHHmeIVzKDJiaILzJIJ6KGGucHjhd4Nz\WWwIHPvcZBmfGm2aX;uJIF{e2G7LDDJR|UxRTBwMECz{txO M4HudVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{[yNlM3Lz5zOUe2NlI{PjxxYU6=
HBCx-10 M3nQPWZ2dmO2aX;uJIF{e2G7 MUm1JI1oN2up NGfMZ2tRd3SnboTpZZRqd25ib3[gbZJqdm:2ZXPhck1qdmS3Y3XkJJR2dW:{IILl[5Jme3Orb36gZYdicW6|dDDoeY1idiCKQlP4MVExKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHntcZVvd2OxbYDyc41qe2WmIH3veZNmKGG2IEWgcYcwc2duIIDvJJFlKGGmbXnubZN1\XKnZDDvckBl[Xm|IEGgeI8hOyCxZjD3[YVsdHliY4njcIU> NYjxT|hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzZpPkG5O|YzOjN4PD;hQi=>
U87MG NGr0XYRHfW6ldHnvckBie3OjeR?= NYrFboZrOiCqcoO= MkDsTY5pcWKrdHnvckBw\iCvVF;SR|EhcW5iaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1\WRiU{[gdoljd3OxbXHsJJBzd3SnaX6gLHNmejJ|NT:yN|YqKGyndnXsJIFnfGW{IEKgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmduIFnDOVA:OC5zzszN NEH4WHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe2NlI{Pid-MUm3OlIzOzZ:L3G+
U87MG NVfHSlh{TnWwY4Tpc44h[XO|YYm= Mk\2NkBpenN? MmXlTY5pcWKrdHnvckBw\iCvVF;SR|IhcW5iaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1\WRiQVvUJEhU\XJ2N{OpJIxmfmWuIHHmeIVzKDJiaILzJIJ6KFenc4Tldo4h[myxdITpcoctKEmFNUC9NE4yPc7:TR?= NYTjPW9TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OlIzOzZpPkG5O|YzOjN4PD;hQi=>
T47D NY\mdnR7SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mn2xNVIxKGi{cx?= NYP1Wll[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIFnfGW{IEGyNEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuN|XPxE1? NFyz[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe2NlI{Pid-MUm3OlIzOzZ:L3G+
HEK293 MWPGeY5kfGmxbjDhd5NigQ>? M1W1OWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSmxCTy22YXfn[YQhdVSRUjCoNVM3OiC2bzCyOVQ6MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9NE4xODJ3zszN NUTMXJc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|U4QTNpPkKzN|c2Pzl|PD;hQi=>
MDA-MB-468 MV\GeY5kfGmxbjDhd5NigQ>? MYWyJIhzew>? MV;Jcohq[mm2aX;uJI9nKG2WT2LDNkBqdiCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bi\nSncjCyJIhzeyxiSVO1NF0xNjJ2zszN MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5NUe5N{c,OjN|N{W3PVM9N2F-
MDA-MB-468 NXLKfmk1TnWwY4Tpc44h[XO|YYm= MmjUNkBpenN? MXnJcohq[mm2aX;uJI9nKG2WT2LDNUBqdiCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwV|YheGixc4Doc5J6dGG2aX;uJIF1KFOnckKzOU8zOzZiYX\0[ZIhOiCqcoOsJGlEPTB;MD62Ou69VQ>? MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{W3PVMoRjJ|M{e1O|k{RC:jPh?=
HEK293 M1\YSGZ2dmO2aX;uJIF{e2G7 NH\lenY{OCCvaX7z M1Hqd2lvcGmkaYTpc44hd2ZibWTPVmMyKGmwIFjFT|I6OyClZXzsd{B2e2mwZzDHV3QufGGpZ3XkJHM3UzFib4KgRYt1OSCjczDzeYJ{fHKjdHWgZYZ1\XJiM{CgcYlveyCkeTDpcY12dm:kbH;0eIlv\yCjc4PhfUwhUUN3ME2wMlAy|ryP NULpT2tXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNVE1QDBpPkK5NlEyPDhyPD;hQi=>
PC3 NYfhc2JQTnWwY4Tpc44h[XO|YYm= NV3iVXNbOTByIH3nM4to NVXGcGtnUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDQR|Mh[2WubIOgfIVvd2e{YX\0JI1wfXOnIH3v[IVtKGG2IEGwNEBu\y:tZzygdI8he2mwZ3zlJIRwe2VibXXhd5Vz\WRidYCgeI8hQCCqcoO= M{H2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkGxOFgxLz5{OUKxNVQ5ODxxYU6=
PC3 MVnBcpRqfHWvb4KgZZN{[Xl? MUmzNEBu\y:tZx?= MnjLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIjlco9oemGodDDtc5V{\SCvb3TlcEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCzNEBu\y:tZzygdI8h[mmmIHnuJJBz\XOnbnPlJI9nKDFvYX3pco9j\W68b4TybYF7d2yn M1na[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkGxOFgxLz5{OUKxNVQ5ODxxYU6=
PC3 MVzBcpRqfHWvb4KgZZN{[Xl? M{[zVFYxKG2pL3vn MYTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNieHXuc4dz[W[2IH3veZNmKG2xZHXsJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IE[wJI1oN2upLDDwc{BjcWRiaX6gdJJme2WwY3Wgc4YhOS2jbXnuc4JmdnqxdILpZZpwdGV? NIj4UIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKxNVQ5OCd-MkmyNVE1QDB:L3G+
HEK293 MXXGeY5kfGmxbjDhd5NigQ>? Mo\CN|AhdWmwcx?= NHn3RnlKdmirYnn0bY9vKG:oIH3UU3JEOiCrbjDISWszQTNiY3XscJMhfXOrbnegS3NVNXSjZ3fl[EBUPktzIH;yJGFsfDFiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveJRqdmdiYYPzZZktKEmFNUC9NE4xOc7:TR?= MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MUG0PFAoRjJ7MkGxOFgxRC:jPh?=
SW620 NGHmSnlHfW6ldHnvckBie3OjeR?= NV\0VZd6OjBibXevb4c> NH;HcWFRd3SnboTpZZRqd25ib3[gbZJqdm:2ZXPhck1qdmS3Y3XkJJR2dW:{IILl[5Jme3Orb36gZYdicW6|dDDoeY1idiCVV{[yNEBk\WyuczD4[Y5w\3KjZoTl[EBqdiCrbX31co9kd22ycn;tbZNm\CCvb4Xz[UBifCB{MDDt[{9s\yxicH:gdYQh[WSvaX7pd5RmemWmIH;uJIRigXNiMjD0c{A1KG:oIIfl[YttgSCleXPs[S=> NHzjOo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKxNVQ5OCd-MkmyNVE1QDB:L3G+
SJ-GBM2 M1LFcpFJXFNiYYPzZZk> MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NU\YWVJ1eUiWUzDhd5NigQ>? M2roXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NU\0U|FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC MU\xTHRUKGG|c3H5 MonCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MmruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NGXEZoxyUFSVIHHzd4F6 NELsW3ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MlnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NV\KcGxxeUiWUzDhd5NigQ>? NUnEWFl4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 M4nETZFJXFNiYYPzZZk> M4LhdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= M2HLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MUTxTHRUKGG|c3H5 MnfCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NF\TVZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NGT4VXNyUFSVIHHzd4F6 NUPLb2NveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NWfqbIxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MVXxTHRUKGG|c3H5 M1K5XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 NVS1dnhFeUiWUzDhd5NigQ>? MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NEnIO4ZyUFSVIHHzd4F6 NFrnUoRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{ NHTZVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NIjae|RyUFSVIHHzd4F6 NEDNWG9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUi2JQl2yJINmdGy| NIrFN|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
U-2 OS NGS4R|hyUFSVIHHzd4F6 NWLERpJPeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NFHqZo9yUFSVIHHzd4F6 NFHKRmFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MWDxTHRUKGG|c3H5 MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?= MkfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M2LCb5FJXFNiYYPzZZk> MoDmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 MV;xTHRUKGG|c3H5 MnP1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> M4PBdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MlXydWhVWyCjc4PhfS=> MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{ NXnLTJpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-S6K / S6K / p-4E-BP1 / E7 / E6 / p53 ; p-mTOR 28115701 24262658
In vivo Ku0063794 inhibits tumor growth and mTOR signaling in a preclinical renal cell carcinoma model. However, Ku0063794 was not more effective than temsirolimus in the animal study. A possible explanation for lack of greater activity in vivo for Ku0063794 is that temsirolimus has important effects on the tumor microenvironment. Temsirolimus decreased angiogenesis in the xenograft tumors while Ku0063794 did not. Temsirolimus treated tumors expressed less VEGF and PDGF than Ku0063794 treated tumors, thus stimulating less angiogenesis[2].

Protocol (from reference)

Kinase Assay:

[1]

  • mTOR complexes kinase assays:

    HEK-293 cells are freshly lysed in Hepes lysis buffer. Lysate (1-4 mg) is pre-cleared by incubating with 5-20 μL of Protein G-Sepharose conjugated to pre-immune IgG. The lysate extracts are then incubated with 5-20 μL of Protein G-Sepharose conjugated to 5-20 μg of either anti-Rictor or anti-Raptor antibody, or pre-immune IgG. All antibodies are covalently conjugated to Protein G-Sepharose. Immunoprecipitations are carried out for 1 hour at 4 °C on a vibrating platform. The immunoprecipitates are washed four times with Hepes lysis buffer, followed by two washes with Hepes kinase buffer. For Raptor immunoprecipitates used for phosphorylating S6K1, for the initial two wash steps the buffer includes 0.5 M NaCl to ensure optimal kinase activity. GST-Akt1 is isolated from serum-deprived HEK-293 cells incubated with PI-103 (1 μM for 1 hour). GST-S6K1 is purified from serum-deprived HEK-293 cells incubated with rapamycin (0.1 μM for 1 hour). mTOR reactions are initiated by adding 0.1 mM ATP and 10 mM MgCl2 in the presence of various concentrations of KU-0063794 and GST-Akt1 (0.5 μg) or GST-S6K1 (0.5 μg). Reaction are carried out for 30 minutes at 30 °C on a vibrating platform and stopped by addition of SDS sample buffer. Reaction mixtures are then filtered through a 0.22-μm-poresize Spin-X filter and samples are subjected to electrophoresis and immunoblot analysis with the indicated antibodies.

Cell Research:

[1]

  • Cell lines: Wild-type and mLST8 deficient MEFs
  • Concentrations: Dissolved in DMSO, final concentration ~3 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method:

    Cells are treated with KU-0063794 for 24, 48, and 72 hours, and the medium is changed every 24 hours with freshly dissolved KU-0063794. For the measurement of cell growth, cells are washed once with PBS, and fixed in 4% (v/v) paraformaldehyde in PBS for 15 minutes. After washing once with water, the cells are stained with 0.1% Crystal Violet in 10% ethanol for 20 minutes and washed three times with water. Crystal Violet is extracted from cells with 0.5 mL of 10% (v/v) ethanoic (acetic) acid for 20 minutes. The eluate is then diluted 1:10 in water and absorbance at 590 nm is quantified. For the assessment of cell cycle distribution, cells are harvested by trypsinization, washed once in PBS, and re-suspended in ice-cold aq. 70% (v/v) ethanol. Cells are washed twice in PBS plus 1% (w/v) BSA and stained for 20 minutes in PBS plus 0.1% (v/v) Triton X-100 containing 50 g/mL propidium iodide and 50 g/mL RNase A. The DNA content of cells is determined using a FACSCalibur flow cytometer and CellQuest software. Red fluorescence (585 nm) is acquired on a linear scale, and pulse width analysis is used to exclude doublets. Cell-cycle distribution is determined using FlowJo software.

  • (Only for Reference)
Animal Research:

[2]

  • Animal Models: Nu/Nu nude mice
  • Dosages: 8 mg/kg
  • Administration: i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 16 mg/mL
(34.36 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 465.54
Formula

C25H31N5O4

CAS No. 938440-64-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CN(CC(O1)C)C2=NC3=C(C=CC(=N3)C4=CC(=C(C=C4)OC)CO)C(=N2)N5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy KU-0063794 | KU-0063794 supplier | purchase KU-0063794 | KU-0063794 cost | KU-0063794 manufacturer | order KU-0063794 | KU-0063794 distributor